CNS Pharmaceuticals Inc saw its stock price leap 257.5% on Monday following disclosure of a private placement that is expected to raise approximately $22.5 million in gross proceeds.
Under securities purchase agreements, the company agreed to sell 650,000 shares of common stock at $2.30 per share, and pre-funded warrants to acquire 9,143,479 shares at $2.299 per warrant. The pre-funded warrants carry an exercise price of $0.001 per share. Institutional healthcare investors participating in the offering include ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners.
The transaction is scheduled to close on or about May 5, 2026, subject to customary closing conditions. A.G.P./Alliance Global Partners served as the sole placement agent for the financing.
CNS stated that net proceeds will be applied to identify and acquire differentiated clinical-stage assets that have clear development pathways and near-term value catalysts, aligning with a corporate strategy the company announced on March 11, 2026. The funds will also be used for working capital and general corporate purposes.
"With the proceeds from this financing, the Company is now in a strong position to execute on our recently announced corporate strategy and capitalize on opportunities created by the dynamic biotech environment over the last several years," said Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals.
Simultaneously, CNS is pursuing out-licensing discussions for its legacy glioblastoma multiforme programs, Berubicin and TPI-287, with the stated aim of reallocating resources toward building a new, acquisition-driven pipeline.
The securities in the private placement will be sold under an exemption from registration under Section 4(a)(2) of the Securities Act of 1933 and Regulation D. CNS also said it intends to file a registration statement with the U.S. Securities and Exchange Commission to register the resale of the securities issued in the offering.
Investors reacted to the financing announcement with a sharp bid for CNS shares, driving the intraday move. The company has outlined a shift in corporate focus and provided specific financing mechanics and timetable for closing, while noting customary conditions and regulatory steps related to the resale registration.
Contextual notes: The company provided a clear breakdown of the securities offered, the per-unit pricing, the identity of participating institutional healthcare investors, the expected use of proceeds, the placement agent, and the regulatory exemptions under which the securities are being sold. The filing and closing timetable are described as expected but remain subject to customary conditions.